IONIS PHARMACEUTICALS INC
TRYNGOLZA
severe hypertriglyceridemia
Resolved
13days ago
Approval decision · Jun 24, 2026
What's at stake
A final FDA approval decision on TRYNGOLZA for severe hypertriglyceridemia is expected Jun 24, 2026.
Primary source
· SEC 8-K
verified 14h ago
“On June 24, 2026, Ionis Pharmaceuticals, Inc. (“ Ionis ”) issued a press release announcing that the U.S. Food and Drug Administration (“ FDA ”) has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides (“ TG ”) and ”